Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$4.64 USD
+0.05 (1.09%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $4.67 +0.03 (0.65%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GALT 4.64 +0.05(1.09%)
Will GALT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GALT
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
GALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
Other News for GALT
GALT Crossed Above 20 Day Moving Average on September 17
GALT Fell Below 20 Day Moving Average on September 16
20 Day Moving Average Support appears for GALT after 16.2% move
12 Health Care Stocks Moving In Monday's After-Market Session
New 52 Week High appears for GALT after 9.6% move